Healthcare - Oncology
Companies developing cancer therapeutics, diagnostics, and precision oncology tools
Immunotherapy & Immuno-Oncology77
Targeted Therapy & Precision Oncology94
Cell & Gene Therapy for Cancer34
Radiopharmaceuticals & ADCs11
Cancer Diagnostics & Biomarkers28
| Ticker | Company | Sub-Theme | Mkt Cap▼ | Price | Chg% | Volume |
|---|---|---|---|---|---|---|
 LLY | Eli Lilly & Co. | Targeted Therapy & Precision Oncology | $0.8t | $928.04 | -0.8% | 95.5K |
 JNJ | Johnson & Johnson | Immunotherapy & Immuno-Oncology | $0.6t | $242.26 | -0.3% | 177.2K |
 ABBV | ABBVIE INC. | Immunotherapy & Immuno-Oncology | $377.0b | $207.25 | -0.8% | 87.7K |
 AZN | AstraZeneca PLC | Immunotherapy & Immuno-Oncology | $300.7b | $203.95 | +0.2% | 28.2K |
 MRK | Merck & Co., Inc. | Immunotherapy & Immuno-Oncology | $292.0b | $120.78 | -0.1% | 192.5K |
 AMGN | Amgen Inc | Immunotherapy & Immuno-Oncology | $188.1b | $344.86 | -0.9% | 43.6K |
 GILD | Gilead Sciences Inc | Cell & Gene Therapy for Cancer | $169.2b | $139.37 | -0.2% | 83.7K |
 BMY | Bristol-Myers Squibb Co. | Immunotherapy & Immuno-Oncology | $122.0b | $59.05 | -0.9% | 243.2K |
 REGN | Regeneron Pharmaceuticals Inc | Immunotherapy & Immuno-Oncology | $79.2b | $760.33 | -0.2% | 18.1K |
 NTRA | Natera, Inc. Common Stock | Cancer Diagnostics & Biomarkers | $26.5b | $206.07 | -0.9% | 15.1K |
 RPRX | Royalty Pharma plc Class A Ordinary Shares | Immunotherapy & Immuno-Oncology | $19.9b | $48.03 | -1.1% | 48.5K |
 MRNA | Moderna, Inc. Common Stock | Immunotherapy & Immuno-Oncology | $19.1b | $48.92 | -0.6% | 153.4K |
 RVMD | Revolution Medicines, Inc. Common Stock | Targeted Therapy & Precision Oncology | $18.4b | $98.00 | -1.1% | 48.6K |
 INCY | Incyte Genomics Inc | Targeted Therapy & Precision Oncology | $18.0b | $95.07 | -0.9% | 28.6K |
 GH | Guardant Health, Inc. Common Stock | Cancer Diagnostics & Biomarkers | $11.3b | $92.20 | -1.7% | 31.7K |
 JAZZ | Jazz Pharmaceuticals, Inc. | Targeted Therapy & Precision Oncology | $11.3b | $185.58 | -0.7% | 8.2K |
 EXEL | Exelixis Inc | Targeted Therapy & Precision Oncology | $10.9b | $43.88 | -0.0% | 38.7K |
 NUVL | Nuvalent, Inc. Class A Common Stock | Targeted Therapy & Precision Oncology | $7.6b | $103.99 | -1.4% | 14.5K |
 HALO | Halozyme Therapeutics, Inc. | Targeted Therapy & Precision Oncology | $7.4b | $64.31 | -0.3% | 18.4K |
 IBRX | ImmunityBio, Inc. Common Stock | Immunotherapy & Immuno-Oncology | $6.8b | $7.52 | +3.0% | 1.5M |
 ACLX | Arcellx, Inc. Common Stock | Cell & Gene Therapy for CancerImmunotherapy & Immuno-Oncology | $6.7b | $114.77 | -0.0% | 36.5K |
 COGT | Cogent Biosciences, Inc. Common Stock | Targeted Therapy & Precision Oncology | $5.7b | $35.38 | +0.5% | 20.3K |
 CGON | CG Oncology, Inc. Common stock | Immunotherapy & Immuno-Oncology | $5.4b | $68.26 | +1.2% | 20.2K |
 CELC | Celcuity Inc. Common Stock | Targeted Therapy & Precision Oncology | $5.2b | $113.14 | +0.5% | 6.6K |
 CAI | Caris Life Sciences, Inc. Common Stock | Cancer Diagnostics & Biomarkers | $4.8b | $19.56 | +1.4% | 40.7K |
 LNTH | Lantheus Holdings, Inc | Radiopharmaceuticals & ADCs | $4.8b | $76.17 | +0.1% | 30.9K |
 ERAS | Erasca, Inc. Common Stock | Targeted Therapy & Precision Oncology | $4.6b | $17.94 | +0.8% | 207.1K |
 CORT | Corcept Therapeutics Inc. | Targeted Therapy & Precision Oncology | $4.1b | $42.03 | -1.1% | 13.9K |
 BLLN | BillionToOne, Inc. Class A Common Stock | Cancer Diagnostics & Biomarkers | $3.2b | $81.83 | +3.1% | 1.8K |
 IDYA | IDEAYA Biosciences, Inc. Common Stock | Targeted Therapy & Precision Oncology | $2.8b | $33.11 | +1.1% | 18.0K |
 TNGX | Tango Therapeutics, Inc. | Targeted Therapy & Precision Oncology | $2.7b | $21.66 | +0.1% | 135.9K |
 RCUS | Arcus Biosciences, Inc. | Immunotherapy & Immuno-Oncology | $2.6b | $22.94 | -0.1% | 22.8K |
 VCYT | Veracyte, Inc. | Cancer Diagnostics & Biomarkers | $2.4b | $32.34 | +0.3% | 9.1K |
 DAWN | Day One Biopharmaceuticals, Inc. Common Stock | Targeted Therapy & Precision Oncology | $2.2b | $21.45 | +0.0% | 28.6K |
 IMNM | Immunome, Inc. | Targeted Therapy & Precision OncologyRadiopharmaceuticals & ADCs | $2.2b | $22.18 | +1.6% | 20.2K |
 SNDX | Syndax Pharmaceuticals, Inc. | Immunotherapy & Immuno-Oncology | $2.0b | $25.37 | +0.9% | 57.8K |
 ADPT | Adaptive Biotechnologies Corporation Common Stock | Cancer Diagnostics & Biomarkers | $2.0b | $14.62 | -1.3% | 29.4K |
 GRAL | GRAIL, Inc. Common Stock | Cancer Diagnostics & Biomarkers | $1.9b | $54.85 | -0.3% | 38.1K |
 NKTR | Nektar Therapeutics | Immunotherapy & Immuno-Oncology | $1.9b | $76.67 | -0.4% | 10.1K |
 TYRA | Tyra Biosciences, Inc. Common Stock | Targeted Therapy & Precision Oncology | $1.9b | $39.16 | -1.1% | 66.2K |
 ZYME | Zymeworks Inc. | Targeted Therapy & Precision Oncology | $1.8b | $26.14 | +1.3% | 20.5K |
 RLAY | Relay Therapeutics, Inc. Common Stock | Targeted Therapy & Precision Oncology | $1.7b | $13.00 | +3.7% | 148.5K |
 NRIX | Nurix Therapeutics, Inc. Common stock | Targeted Therapy & Precision Oncology | $1.5b | $15.52 | +0.0% | 28.1K |
 DMRA | Damora Therapeutics, Inc. Common Stock | Targeted Therapy & Precision Oncology | $1.5b | $25.44 | +1.4% | 8.8K |
 NUVB | Nuvation Bio Inc. | Targeted Therapy & Precision Oncology | $1.4b | $4.46 | +1.2% | 203.2K |
 NTLA | Intellia Therapeutics, Inc | Cell & Gene Therapy for Cancer | $1.4b | $13.40 | +2.1% | 90.2K |
 IOVA | Iovance Biotherapeutics, Inc. Common Stock | Cell & Gene Therapy for CancerImmunotherapy & Immuno-Oncology | $1.4b | $3.43 | -0.1% | 327.0K |
 ORIC | Oric Pharmaceuticals, Inc. Common Stock | Targeted Therapy & Precision Oncology | $1.4b | $8.85 | -0.5% | 135.5K |
 VIR | Vir Biotechnology, Inc. Common Stock | Targeted Therapy & Precision Oncology | $1.4b | $8.98 | -0.9% | 64.7K |
 IMTX | Immatics N.V. Ordinary Shares | Cell & Gene Therapy for CancerImmunotherapy & Immuno-Oncology | $1.2b | $10.53 | +1.7% | 15.9K |